As MAFLD is linked with insulin resistance [131,132], their ability to enhance insulin sensitivity also means that SGLT2 inhibitors may decrease hepatic glucose production and reduce circulating free fatty acid levels [51]. This evidence concerns the gene INS and Insulin resistance.